SCHEDULE 13G/A: BlackRock Discloses 13.9% Stake in Catalyst Pharmaceuticals

BlackRock, Inc. has filed an amended Schedule 13G, revealing a beneficial ownership of 13.9% of Catalyst Pharmaceuticals, Inc.'s common stock as of March 31, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 16,892,951 shares of Catalyst Pharmaceuticals, Inc. common stock.
• This represents 13.9% of the total outstanding common stock of Catalyst Pharmaceuticals, Inc.
• BlackRock holds sole voting power over 16,781,105 shares and sole dispositive power over 16,892,951 shares.
• The filing is an Amendment No. 9 to a Schedule 13G, indicating previous filings.
• BlackRock states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• iShares Core S&P Small-Cap ETF, a BlackRock entity, holds more than 5% of Catalyst Pharmaceuticals' common stock.

Sentiment

Score: 5

Explanation: The document is a factual regulatory filing disclosing an ownership stake, which is neutral in sentiment regarding the issuer's performance. It indicates significant institutional interest but provides no positive or negative operational news.

Future Outlook

This Schedule 13G filing does not provide any forward-looking statements or guidance regarding Catalyst Pharmaceuticals, Inc.'s future performance or operations.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

Schedule 13G filings are routine disclosures by institutional investors like BlackRock when their beneficial ownership in a public company exceeds 5%. These filings indicate a passive investment intent, meaning the investor does not seek to control or influence the management of the company. For Catalyst Pharmaceuticals, this filing confirms significant institutional backing from one of the world's largest asset managers.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional shareholder's stake, potentially signaling confidence from a major asset manager.
• Management: Awareness of a large, passive institutional holder, which typically does not seek to influence control.

Key Dates

Keywords

BlackRock, Catalyst Pharmaceuticals, Schedule 13G, Institutional Ownership, Common Stock, SEC Filing, Investment Management, Passive Investment, Shareholding, Biotechnology, Pharmaceuticals